Particularly, the expression of the following genes was affected in A172 cells after 24 h of treatment with TRAIL: VEGF, the MMP-2, the gene encoding TIMP-2, a protein regulating the activity of MMP-2 and SPARC, a protein involved in glioblastoma invasiveness processes (Figure 2A). Here, SPARC is linked to glioblastoma.